Filing Details

Accession Number:
0001567619-19-019579
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-15 18:24:16
Reporting Period:
2019-10-10
Accepted Time:
2019-10-15 18:24:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
827871 Eagle Pharmaceuticals Inc. EGRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1495110 L Douglas Braunstein 570 Lexington Avenue,
35Th Floor
New York NY 10022
Yes No No No
1652522 Hudson Executive Capital Lp 570 Lexington Avenue
35Th Floor
New York NY 10022
Yes No No No
1700567 Hec Management Gp Llc 570 Lexington Avenue
35Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-10-10 7,829 $60.16 796,077 No 4 S Indirect See footnotes
Common Stock Disposition 2019-10-11 16,300 $60.39 779,777 No 4 S Indirect See footnotes
Common Stock Disposition 2019-10-15 3,909 $62.63 775,868 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Footnotes
  1. The sale of shares set forth herein is made pursuant to a sales plan under Rule 10b5-1(c).
  2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.0000 to $60.4900, inclusive. The Reporting Persons (defined below) undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
  3. In addition to Hudson Executive Capital LP, a Delaware limited liability company ("Hudson Executive"), this Form 4 is being filed jointly by HEC Management GP LLC, a Delaware limited liability company ("Management GP"), and Douglas L. Braunstein, a citizen of the United States of America (together with Hudson Executive and Management GP, the "Reporting Persons"), each of whom has the same business address as Hudson Executive and may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the "Subject Securities").
  4. Hudson Executive, as the investment adviser to certain affiliated investment funds, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. Management GP, as the general partner of Hudson Executive, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a). By virtue of Mr. Braunstein's position as Managing Partner of Hudson Executive and Managing Member of Management GP, Mr. Braunstein may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) and Hudson Executive and Management GP may be deemed to be the beneficial owner of the Subject Securities held by Mr. Braunstein.
  5. Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.0000 to $61.1200, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.5000 to $62.9300, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.